Genzyme and FIOCRUZ Collaborate to Advance Drugs for Neglected Diseases
Genzyme Corp. (Cambridge, MA, www.genzyme.com) and the Oswaldo Cruz Foundation (FIOCRUZ, www.fiocruz.br) have announced plans to collaborate on research into new drugs focusing on neglected diseases.
Genzyme Corp. (Cambridge, MA, www.genzyme.com) and the Oswaldo Cruz Foundation (FIOCRUZ, www.fiocruz.br) have announced plans to collaborate on research into new drugs focusing on neglected diseases.
The companies will initially focus on two specific research programs. The first will focus on identifying new biological targets within the parasite that causes Chagas disease and will include screening for potential compounds that affect these targets and which could be developed into drugs. The second program will test the effectiveness of using monoclonal antibodies to neutralize a protein that contributes to heart damage in Chagas disease, known as transforming growth factor-beta.
The partnership agreement includes an innovative approach to intellectual property rights, providing FIOCRUZ rights to commercial uses within the field of neglected diseases on a royalty-free basis.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
